OPKO Health subsidiary ModeX Therapeutics has started dosing patients with its tetraspecific T-cell engager, MDX2003, for ...
Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas Preclinical studies presented at 2025 American Society of ...
Researchers assessed whether using bispecific antibodies targeting CD20 and CD3 would reduce efficacy or increase toxicity in patients with relapsed or refractory non-Hodgkin B-cell lymphomas ...
Researchers found that loss of HDAC7 disrupted B-cell maturation in mouse models. Restoring HDAC7 suppressed tumor growth, ...
First-in-human clinical trial underway to evaluate safety, tolerability and pharmacodynamic activity of HB2198 in normal healthy volunteers. A ...
Metabolic tumor volume—a biomarker derived from PET imaging—can more accurately predict progression-free survival for large B ...
Key market opportunities for BCMA-targeted therapies include rising multiple myeloma cases, next-gen therapy approvals, ...
ModeX Therapeutics initiates clinical trial of tetraspecific antibody for treatment of B-cell lymphomas: Weston, Massachusetts Friday, April 24, 2026, 16:00 Hrs [IST] ModeX Therap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results